2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1984

Which Factors Associate with Localized Knee Pain and Generalized Pain: A 10-Year Longitudinal Study?
Abstract Number: 682

Which Is the Most Reliable Imaging Method for Detection of Structural Changes in the Sacroiliac Joints of Patients with Ankylosing Spondylitis? a Cross-Sectional Study Comparing MRI, CT and Conventional Radiographs
Abstract Number: 78

Whole Blood Gene Modules Show Differences Between Active Lupus Nephritis and Quiescent Disease As Well As Absence of Plasmablast Signature in This Adult Population
Abstract Number: 2862

Whole Blood Phenotyping and Innate and Adaptive Stimulation Reveal Unique Differences in Granulocytes and Innate Pathways of African American SLE Patients with Variable Disease Activity
Abstract Number: 2036

Whole Exome Sequencing in Early Onset Systemic Lupus Erythematosus
Abstract Number: 2667

Whole Frequency Audiometrical Correlation with Disease Activity in Primary SjöGren’s Syndrome in Hispanic Population
Abstract Number: 802

Whole Transcriptome Profiling through RNA Sequencing Reveals Differentially Expressed Sense-Antisense Gene Pairs in Patients with Systemic Sclerosis
Abstract Number: 431

Wide Variations in Hepatitis B Screening Practices for Patients Receiving Rituximab
Abstract Number: 2995

WISP1/CCN4 Aggravates Experimental Osteoarthritis and Is Associated with Disease Progression in Early Osteoarthritis Patients
Abstract Number: 766

Withdrawal of Mycophenolate Mofetil after Maintenance Treatment of SLE Nephritis Associated with Renal Relapse
Abstract Number: 2657

Withdrawal of Nonsteroidal Anti-Inflammatory Drugs in Rheumatoid Arthritis Patients with Low Disease Activity
Abstract Number: 35

WITHDRAWN
Abstract Number: 287

WITHDRAWN
Abstract Number: 384

WITHDRAWN
Abstract Number: 623

WITHDRAWN

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].